In simple terms
Every time a cancer cell divides, errors can slip into its genetic blueprint. Tumour mutational burden is a score that counts how many of these genetic spelling mistakes exist within a given sample of cancer DNA. When a tumour has a large quantity of mutations—called 'TMB-high'—it produces unusual surface proteins that look distinctly foreign. This makes it far easier for your immune system's T cells to spot the cancer once checkpoint inhibitor medications release the molecular brakes.
Key takeaways
- TMB measures the number of somatic mutations per megabase of DNA.
- High TMB typically correlates with increased neoantigen production.
- A score of 10 mutations/Mb or higher is widely considered 'TMB-high'.
- Next-generation genomic sequencing is required to determine the score.
Definition
Tumour mutational burden measures the frequency of somatic mutations per megabase (mut/Mb) of sequenced DNA. Malignant cells accumulate genetic alterations over time due to endogenous replication errors, defective DNA mismatch repair pathways, or exposure to external mutagens like ultraviolet light and tobacco smoke.
A high mutational load leads to an increased generation of 'neoantigens'—novel, aberrant peptides presented on cancer cell surfaces. Because these neoantigens appear foreign to the host immune system, tumours with high TMB are generally more immunogenic. Consequently, TMB has emerged as an essential, tissue-agnostic predictive biomarker in precision oncology.
Why it matters
Knowing your tumour mutational burden score provides crucial direction when standard lines of therapy are exhausted or when assessing the likelihood of response to checkpoint inhibitors. A TMB-high status can qualify patients for specific approved immunotherapies regardless of where the cancer originally began in the body, opening up targeted treatment options that might otherwise not have been considered.
Related biomarkers and tests
TMB is assessed using next-generation sequencing (NGS) performed on formalin-fixed tumour tissue obtained from a surgical specimen or biopsy. Comprehensive genomic profiling panels analyse hundreds of genes across target megabases. Blood-based assays (bTMB) evaluating circulating tumour DNA are also utilised when tissue is insufficient.
Related cancers
Elevated TMB is commonly identified in malignancies linked to environmental mutagens, such as melanoma (UV radiation) and non-small cell lung cancer (tobacco carcinogens). It also occurs in colorectal, endometrial, gastric, and bladder cancers exhibiting microsatellite instability or defective DNA mismatch repair pathways.
Related treatments
A finding of TMB-high (conventionally defined as 10 or more mutations per megabase) often leads to treatment with immune checkpoint inhibitors, such as pembrolizumab, in approved settings. Conversely, low TMB suggests immunotherapy alone may have lower efficacy, directing clinicians towards chemotherapy, targeted molecular therapies, or combination regimens.
Frequently asked questions
Does having a high TMB mean my cancer is more aggressive?
Not necessarily. A high TMB simply means there are many genetic mutations in the tumour's coding regions. While it reflects genomic instability, it also makes the tumour more visible to your immune system, often increasing the chance of responding to immunotherapies.
How is TMB different from testing for a single gene mutation?
Single-gene tests look for specific 'driver' mutations (like EGFR or BRAF) to match with targeted pills. In contrast, TMB counts the total volume of non-specific mutations across the genome to predict how well the immune system might recognise the cancer.
Can I receive immunotherapy if my TMB score is low?
Yes. While a high TMB increases the likelihood of an immunotherapy response, patients with lower scores can still benefit, particularly if their tumours express other biomarkers like PD-L1 or demonstrate microsatellite instability. Treatment decisions consider multiple factors.
References
- 1.Genomic Testing and Biomarkers— National Cancer Institute
- 2.Understanding Biomarkers and Next-Generation Sequencing— American Society of Clinical Oncology
- 3.ESMO Recommendations on the Use of Tumour Mutational Burden— European Society for Medical Oncology
Ask GetOnco AI
Get personalised answers about Tumor Mutational Burden — Genomic Alteration Count from your AI cancer care coordinator.
- Can you explain Tumor Mutational Burden — Genomic Alteration Count in simple words?
- What does Tumor Mutational Burden — Genomic Alteration Count mean for my treatment plan?
- What questions should I ask my oncologist about Tumor Mutational Burden — Genomic Alteration Count?
- What next steps do you recommend regarding Tumor Mutational Burden — Genomic Alteration Count?
GetOnco AI provides educational information and never replaces advice from your medical team.
Explore related topics
More in this section
Glossary terms in this article
Last reviewed August 1, 2026
Medical disclaimer
Educational information only. GetOnco is software, not a medical provider, and does not diagnose disease or recommend treatments. Always discuss your situation with qualified healthcare professionals.